Mitrade Insights is dedicated to providing investors with rich, timely and most valuable financial information to help investors grasp the market situation and find timely trading opportunities.

2021

Best News & Analysis Provider

FxDailyInfo

2022

Best Forex Educational Resources Global

International Business Magazine

Insights

News

Johnson & Johnson Stock (JNJ) Moved Up by 3.48% on Oct 22: Facts Behind the Movement

Source Tradingkey

Johnson & Johnson (JNJ) moved up by 3.48%. The Pharmaceuticals & Medical Research sector is up by 1.73%. The company outperformed the industry. Top 3 stocks by turnover in the sector: Eli Lilly and Co (LLY) up 3.35%; Qiagen NV (QGEN) up 0.47%; Moderna Inc (MRNA) down 9.75%.

SummaryOverview

What is driving Johnson & Johnson (JNJ)’s stock price up today?

Johnson & Johnson advanced sharply as positive clinical trial data from its medical technology portfolio boosted investor optimism surrounding its high-growth electrophysiology franchise. The company presented groundbreaking real-world data from its VARIPURE and Omny-IRE studies at the Asia Pacific Heart Rhythm Society 2026 Annual Meeting. The VARIPURE study demonstrated complete acute procedural success and an exceptionally clean safety profile using the VARIPULSE Pro Platform for atrial fibrillation ablation, while the 12-month Omny-IRE trial confirmed strong long-term arrhythmia freedom. The peer-reviewed findings reinforced the company's technological leadership in cardiovascular care and highlighted expanding commercial potential in MedTech.

The bullish clinical momentum built upon a solid foundation established by the company's third-quarter financial results. Although GAAP net income was impacted by one-time legal settlement charges related to talc litigation and strategic M&A expenses, underlying operational performance proved resilient. Strong demand for key oncology therapies and immunology blockbusters offset headwinds from biosimilar competition. Furthermore, management's decision to raise full-year sales and adjusted earnings guidance, alongside maintaining a robust free cash flow outlook, reassured institutional investors regarding the company's long-term earnings durability and dividend coverage.

Broader market dynamics also provided a favorable tailwind. As major equity benchmarks faced downside pressure driven by volatility in high-valuation sectors, institutional capital rotated into defensive, high-quality healthcare leaders. Johnson & Johnson's stable balance sheet, combined with its 64-year streak of annual dividend increases, made it a primary recipient of safe-haven inflows. Coupled with recent price target upgrades from sell-side equity analysts, this defensive sector rotation fueled significant buying volume and intraday price expansion.

Technical Analysis of Johnson & Johnson (JNJ)

Technically, Johnson & Johnson (JNJ) shows a MACD (12,26,9) value of 1.704, indicating a neutral signal. The RSI at 56.843 suggests neutral condition and the Williams %R at 0.000 suggests overbought condition. Please monitor closely.

Fundamental Analysis of Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ) is in the Pharmaceuticals & Medical Research industry. Its latest annual revenue is $94.19B, ranking 3 in the industry. The net profit is $26.80B, ranking 1 in the industry. Company Profile

FundamentalAnalysis

Over the past month, multiple analysts have rated the company as Buy, with an average price target of $274.76, a high of $320.00, and a low of $170.00.

More details about Johnson & Johnson (JNJ)

Company Specific Risks:

Litigation Charges & Unresolved Talc Liabilities: In its recent Form 8-K earnings report, Johnson & Johnson recognized a $5.5 billion litigation charge to resolve talc liabilities—contributing to roughly $7 billion in total legal and transaction costs—which caused Q3 GAAP net earnings to fall 95.9% year-over-year to $210 million ($0.09 per share); full resolution remains at risk pending a strict 95% claimant participation threshold.
MedTech Segment Underperformance & Safety Drag: The MedTech division missed Wall Street sales expectations for a second consecutive quarter with just 2.5% growth to $8.64 billion, impacted by a 2.3% contraction in Abiomed sales following a U.S. Class 1 recall and safety/efficacy concerns surrounding Impella heart pumps, as well as China volume-based procurement pricing pressures.
Severe Patent Cliff Erosion for Stelara: Revenues for flagship immunology drug Stelara plummeted 54% year-over-year to $716 million as cheap biosimilar competition rapidly eroded market share following its loss of exclusivity, placing heavy reliance on oncology offerings to offset top-line growth drags.
Valuation Multiples Premium & Near-Term M&A Dilution: Trading at roughly 23x–28x forward earnings—a ~32.5% premium over intrinsic value estimates—JNJ faces valuation compression risk, amplified by an estimated $0.64 per share in near-term EPS dilution from recent transactions including the Firefly Bio acquisition and Sail Biomedicines collaboration.

Source

Disclaimer: For information purposes only. Past performance is not indicative of future results.

Recommended Articles

Dollar presses 102 as the 10-year yield sits at 5.14% — and October hike odds are only 17%The dollar index closed at 101.99 (+0.20%) on Monday after briefly topping 102.07, while the 10-year Treasury yield rose to 5.14% and the 2-year hit 4.774% — yet futures price only about a 17% chance of a hike at the October 27-28 FOMC, versus roughly 90% for December. The driver is a global bond selloff, not a Fed repricing: France's 10-year OAT jumped to 4.84% ~ 4.94% and the OAT-Bund spread widened to 140 ~ 146bp. Here are the levels, the cross-asset read-through and what to watch.

Author Irene Q.

Oct 20, Tue

The dollar index closed at 101.99 (+0.20%) on Monday after briefly topping 102.07, while the 10-year Treasury yield rose to 5.14% and the 2-year hit 4.774% — yet futures price only about a 17% chance of a hike at the October 27-28 FOMC, versus roughly 90% for December. The driver is a global bond selloff, not a Fed repricing: France's 10-year OAT jumped to 4.84% ~ 4.94% and the OAT-Bund spread widened to 140 ~ 146bp. Here are the levels, the cross-asset read-through and what to watch.

Meta's AI bill just hit $145 billion — and it issued a new share class to pay for it Meta reported record third-quarter revenue of $64.60 billion, up 26% from a year earlier, and raised full-year 2026 capital expenditure guidance to $135-145 billion from $130-145 billion. To fund that build-out without touching Mark Zuckerberg's voting control, the company announced a 2-for-1 stock split that hands every Class A holder a new non-voting Class C share. Here are the four lines that matter, the peer group that is being re-rated alongside it, and the bull and bear cases.

Author Irene Q.

Oct 22, Thu

Meta reported record third-quarter revenue of $64.60 billion, up 26% from a year earlier, and raised full-year 2026 capital expenditure guidance to $135-145 billion from $130-145 billion. To fund that build-out without touching Mark Zuckerberg's voting control, the company announced a 2-for-1 stock split that hands every Class A holder a new non-voting Class C share. Here are the four lines that matter, the peer group that is being re-rated alongside it, and the bull and bear cases.

The Fed will sit still on October 28 — but 100 of 100 economists now expect a December hike A Reuters poll run October 16-20 found 94 of 100 economists expecting the Fed to hold at 3.75-4.00% on October 28 — and all 100 expecting a hike in December, against less than half a month earlier. The market is close to the same price, with CME FedWatch at roughly 17% for October and 82.8% for December. With the Fed in blackout since October 17, here are the five dates that decide the rest of the year, what each one is priced for, and the two directions each can take.

Author Irene Q.

Oct 22, Thu

A Reuters poll run October 16-20 found 94 of 100 economists expecting the Fed to hold at 3.75-4.00% on October 28 — and all 100 expecting a hike in December, against less than half a month earlier. The market is close to the same price, with CME FedWatch at roughly 17% for October and 82.8% for December. With the Fed in blackout since October 17, here are the five dates that decide the rest of the year, what each one is priced for, and the two directions each can take.

Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - October 23, 2026 Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for October 23, 2026. Read on for the details.

Author Mitrade

Yesterday 02: 56

Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for October 23, 2026. Read on for the details.

Nasdaq closes at 26,008.86 — 8.9 points above 26,000, and the credit market never blinked The Nasdaq Composite fell 2.60% to 26,008.86 on October 22, its worst session since June, as Meta sank 6.98% on 2026 capex guidance of $135–145 billion. But the equal-weight S&P 500 rose 0.73%, high-yield credit was flat and 10-year yields fell 20 basis points. This was an AI de-rating, not a risk-off event — here is the transmission chain, the 29,000 / 28,200 levels and what would prove it wrong.

Author Irene Q.

Yesterday 06: 39

The Nasdaq Composite fell 2.60% to 26,008.86 on October 22, its worst session since June, as Meta sank 6.98% on 2026 capex guidance of $135–145 billion. But the equal-weight S&P 500 rose 0.73%, high-yield credit was flat and 10-year yields fell 20 basis points. This was an AI de-rating, not a risk-off event — here is the transmission chain, the 29,000 / 28,200 levels and what would prove it wrong.

Popular Symbols